Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection

Abstract

Objectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver disease due to hepatitis C virus (HCV) genotype 1b. Materials and Methods: This study included cases who were treated with DAAs after HCV genotype 1b infection. HCV-RNA levels and biochemical and hematological parameters measured at the beginning of treatment, 12th week and 52th week after the treatment were transferred to the SPSS statistics software. model for end-stage liver disease (MELD) and Child-Pugh scores were also calculated and added to these data. Results: The study group consisted of a total of 102 patients, including 33 (32%) males and 69 (68%) females. Compensated cirrhosis was detected in 26.5% of the patients (n=27). There was a significant change in serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alpha-fetoprotein (AFP) parameters in patients with compensated cirrhosis after treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALP and AFP parameters in the group without cirrhosis (p<0.05). Only a significant decrease was observed in the MELD score of the patients with compensated cirrhosis (p=0.007). Conclusion: The ombitasvir/paritaprevir/ritonavir+dasabuvir and ledipasvir/sofosbuvir regimens are very effective and safe in the treatment of patients who develop chronic liver disease and compensated liver cirrhosis after HCV genotype 1b infection.